| Bioactivity | MAPK-IN-1 (Compound 2) is a MAPK signaling pathway inhibitor. MAPK-IN-1 exhibits AChE inhibitory activity with an IC50 of 23.84 μM. MAPK-IN-1 shows anti-neuroinflammatory and neuroprotective activity and can be used for Alzheimer's disease research[1]. |
| Invitro | MAPK-IN-1 (Compound 2) inhibits NO, IL-1β, IL-6, and TNF-α release in BV-2 cells with IC50 values of 0.49 ± 0.17, 1.34 ± 0.21, 9.17 ± 0.17 and 8.17 ± 0.23 μM, respectively[1].MAPK-IN-1 downregulates LPS-induced phosphorylation of JNK, ERK, and p38 in MAPK signaling pathway[1].MAPK-IN-1 inhibits expressions of iNOS, COX-2, and TLR4 in LPS-induced BV-2 cells[1]. |
| Name | MAPK-IN-1 |
| CAS | 2470587-69-8 |
| Formula | C19H18O4 |
| Molar Mass | 310.34 |
| Transport | Room temperature in continental US; may vary elsewhere. |
| Storage | Please store the product under the recommended conditions in the Certificate of Analysis. |
| Reference | [1]. Wu JS, et al. The oxygenated products of cryptotanshinone by biotransformation with Cunninghamella elegans exerting anti-neuroinflammatory effects by inhibiting TLR 4-mediated MAPK signaling pathway. Bioorg Chem. 2020 Nov;104:104246. |